TY - JOUR AU - Esteller, M. PY - 2008 DA - 2008// TI - Epigenetics in cancer JO - N Engl J Med VL - 358 UR - https://doi.org/10.1056/NEJMra072067 DO - 10.1056/NEJMra072067 ID - Esteller2008 ER - TY - JOUR AU - Issa, J. P. AU - Baylin, S. B. AU - Herman, J. G. PY - 1997 DA - 1997// TI - DNA methylation changes in hematologic malignancies: biologic and clinical implications JO - Leukemia VL - 11 ID - Issa1997 ER - TY - JOUR AU - Helm, L. H. AU - Scheepers, E. R. AU - Veeger, N. J. AU - Daenen, S. M. AU - Mulder, A. B. AU - Berg, E. PY - 2013 DA - 2013// TI - Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-29 DO - 10.1186/1756-8722-6-29 ID - Helm2013 ER - TY - JOUR AU - Pleyer, L. AU - Stauder, R. AU - Burgstaller, S. AU - Schreder, M. AU - Tinchon, C. AU - Pfeilstocker, M. PY - 2013 DA - 2013// TI - Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-32 DO - 10.1186/1756-8722-6-32 ID - Pleyer2013 ER - TY - JOUR AU - Bachegowda, L. AU - Gligich, O. AU - Mantzaris, I. AU - Schinke, C. AU - Wyville, D. AU - Carrillo, T. PY - 2013 DA - 2013// TI - Signal transduction inhibitors in treatment of myelodysplastic syndromes JO - J Hematol Oncol VL - 6 UR - https://doi.org/10.1186/1756-8722-6-50 DO - 10.1186/1756-8722-6-50 ID - Bachegowda2013 ER - TY - JOUR AU - Hájková, H. AU - Fritz, M. H. AU - Haškovec, C. AU - Schwarz, J. AU - Šálek, C. AU - Marková, J. PY - 2014 DA - 2014// TI - CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s13045-014-0066-4 DO - 10.1186/s13045-014-0066-4 ID - Hájková2014 ER - TY - JOUR AU - Jabbour, E. AU - Issa, J. P. AU - Garcia-Manero, G. AU - Kantarjian, H. PY - 2008 DA - 2008// TI - Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies JO - Cancer VL - 112 UR - https://doi.org/10.1002/cncr.23463 DO - 10.1002/cncr.23463 ID - Jabbour2008 ER - TY - JOUR AU - Santini, V. AU - Kantarjian, H. M. AU - Issa, J. P. PY - 2001 DA - 2001// TI - Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications JO - Ann Intern Med VL - 134 UR - https://doi.org/10.7326/0003-4819-134-7-200104030-00011 DO - 10.7326/0003-4819-134-7-200104030-00011 ID - Santini2001 ER - TY - JOUR AU - deVos, D. AU - Overveld, W. PY - 2001 DA - 2001// TI - Decitabine: a historical review of the development of an epigenetic drug JO - Ann Hematol VL - 84 UR - https://doi.org/10.1007/s00277-005-0008-x DO - 10.1007/s00277-005-0008-x ID - deVos2001 ER - TY - JOUR AU - Lübbert, M. PY - 2000 DA - 2000// TI - DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action JO - Curr Top Microbiol Immunol VL - 249 ID - Lübbert2000 ER - TY - JOUR AU - Estey, E. H. PY - 2013 DA - 2013// TI - Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2013.173 DO - 10.1038/leu.2013.173 ID - Estey2013 ER - TY - JOUR AU - Kantarjian, H. M. AU - Thomas, X. G. AU - Dmoszynska, A. AU - Wierzbowska, A. AU - Mazur, G. AU - Mayer, J. PY - 2012 DA - 2012// TI - Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia JO - J ClinOncol VL - 30 UR - https://doi.org/10.1200/JCO.2011.38.9429 DO - 10.1200/JCO.2011.38.9429 ID - Kantarjian2012 ER - TY - JOUR AU - Issa, J. P. AU - Gharibyan, V. AU - Cortes, J. AU - Jelinek, J. AU - Morris, G. AU - Verstovsek, S. PY - 2005 DA - 2005// TI - Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinibmesylate JO - J ClinOncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.11.981 DO - 10.1200/JCO.2005.11.981 ID - Issa2005 ER - TY - JOUR AU - Oki, Y. AU - Kantarjian, H. M. AU - Gharibyan, V. AU - Jones, D. AU - O'brien, S. AU - Verstovsek, S. PY - 2007 DA - 2007// TI - Phase II study of low-dose decitabine in combination with imatinibmesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia JO - Cancer VL - 109 UR - https://doi.org/10.1002/cncr.22470 DO - 10.1002/cncr.22470 ID - Oki2007 ER - TY - JOUR AU - Saunthararajah, Y. AU - Molokie, R. AU - Saraf, S. AU - Sidhwani, S. AU - Gowhari, M. AU - Vara, S. PY - 2008 DA - 2008// TI - Clinical effectiveness of decitabine in severe sickle cell disease JO - Br J Haematol VL - 141 UR - https://doi.org/10.1111/j.1365-2141.2008.07027.x DO - 10.1111/j.1365-2141.2008.07027.x ID - Saunthararajah2008 ER - TY - JOUR AU - Kantarjian, H. AU - Issa, J. P. AU - Rosenfeld, C. S. AU - Bennett, J. M. AU - Albitar, M. AU - DiPersio, J. PY - 2006 DA - 2006// TI - Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study JO - Cancer VL - 106 UR - https://doi.org/10.1002/cncr.21792 DO - 10.1002/cncr.21792 ID - Kantarjian2006 ER - TY - JOUR AU - Santos, F. P. AU - Kantarjian, H. AU - Garcia-Manero, G. AU - Issa, J. P. AU - Ravandi, F. PY - 2010 DA - 2010// TI - Decitabine in the treatment of myelodysplastic syndromes JO - Expert Rev Anticancer Ther VL - 10 UR - https://doi.org/10.1586/era.09.164 DO - 10.1586/era.09.164 ID - Santos2010 ER - TY - JOUR AU - Wijermans, P. W. AU - Lübbert, M. AU - Verhoef, G. AU - Klimek, V. AU - Bosly, A. PY - 2005 DA - 2005// TI - An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients JO - Ann Hematol VL - 84 UR - https://doi.org/10.1007/s00277-005-0012-1 DO - 10.1007/s00277-005-0012-1 ID - Wijermans2005 ER - TY - JOUR AU - Lübbert, M. AU - Suciu, S. AU - Baila, L. AU - Rüter, B. H. AU - Platzbecker, U. AU - Giagounidis, A. PY - 2011 DA - 2011// TI - Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.30.9245 DO - 10.1200/JCO.2010.30.9245 ID - Lübbert2011 ER - TY - JOUR AU - Kantarjian, H. M. AU - O'Brien, S. AU - Huang, X. AU - Garcia-Manero, G. AU - Ravandi, F. AU - Cortes, J. PY - 2007 DA - 2007// TI - Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience JO - Cancer VL - 109 UR - https://doi.org/10.1002/cncr.22508 DO - 10.1002/cncr.22508 ID - Kantarjian2007 ER - TY - JOUR AU - Steensma, D. P. AU - Baer, M. R. AU - Slack, J. L. AU - Buckstein, R. AU - Godley, L. A. AU - Garcia-Manero, G. PY - 2009 DA - 2009// TI - Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.6550 DO - 10.1200/JCO.2008.19.6550 ID - Steensma2009 ER - TY - JOUR AU - Joeckel, T. E. AU - Lübbert, M. PY - 2012 DA - 2012// TI - Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update JO - Semin Hematol VL - 49 UR - https://doi.org/10.1053/j.seminhematol.2012.08.001 DO - 10.1053/j.seminhematol.2012.08.001 ID - Joeckel2012 ER - TY - JOUR AU - Goodyear, O. AU - Agathanggelou, A. AU - Novitzky-Basso, I. AU - Siddique, S. AU - McSkeane, T. AU - Ryan, G. PY - 2010 DA - 2010// TI - Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2009-11-249474 DO - 10.1182/blood-2009-11-249474 ID - Goodyear2010 ER - TY - JOUR AU - Choi, J. AU - Ritchey, J. AU - Prior, J. L. AU - Holt, M. AU - Shannon, W. D. AU - Deych, E. PY - 2010 DA - 2010// TI - In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2009-12-257253 DO - 10.1182/blood-2009-12-257253 ID - Choi2010 ER - TY - JOUR AU - Schroeder, T. AU - Fröbel, J. AU - Cadeddu, R. P. AU - Czibere, A. AU - Dienst, A. AU - Platzbecker, U. PY - 2013 DA - 2013// TI - Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2013.64 DO - 10.1038/leu.2013.64 ID - Schroeder2013 ER - TY - JOUR AU - Jabbour, E. AU - Giralt, S. AU - Kantarjian, H. AU - Garcia-Manero, G. AU - Jagasia, M. AU - Kebriaei, P. PY - 2009 DA - 2009// TI - Low‐dose azacitidine after allogeneic stem cell transplantation for acute leukemia JO - Cancer VL - 115 UR - https://doi.org/10.1002/cncr.24198 DO - 10.1002/cncr.24198 ID - Jabbour2009 ER - TY - JOUR AU - Lima, M. AU - Giralt, S. AU - Thall, P. F. AU - Padua, S. L. AU - Jones, R. B. AU - Komanduri, K. PY - 2010 DA - 2010// TI - Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.25500 DO - 10.1002/cncr.25500 ID - Lima2010 ER - TY - JOUR AU - Schroeder, T. AU - Czibere, A. AU - Platzbecker, U. AU - Bug, G. AU - Uharek, L. AU - Luft, T. PY - 2013 DA - 2013// TI - Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2013.7 DO - 10.1038/leu.2013.7 ID - Schroeder2013 ER - TY - JOUR AU - Platzbecker, U. AU - Wermke, M. AU - Radke, J. AU - Oelschlaegel, U. AU - Seltmann, F. AU - Kiani, A. PY - 2012 DA - 2012// TI - Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2011.234 DO - 10.1038/leu.2011.234 ID - Platzbecker2012 ER - TY - JOUR AU - Storer, B. E. PY - 1989 DA - 1989// TI - Design and analysis of phase I clinical trials JO - Biometrics VL - 45 UR - https://doi.org/10.2307/2531693 DO - 10.2307/2531693 ID - Storer1989 ER - TY - JOUR AU - Piantadosi, S. AU - Fisher, J. D. AU - Grossman, S. PY - 1998 DA - 1998// TI - Practical implementation of a modified continual reassessment method for dose-finding trials JO - Cancer ChemotherPharmacol VL - 41 ID - Piantadosi1998 ER - TY - JOUR AU - Wallin, J. E. AU - Friberg, L. E. AU - Karlsson, M. O. PY - 2010 DA - 2010// TI - Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information JO - Basic Clin Pharmacol Toxicol VL - 106 UR - https://doi.org/10.1111/j.1742-7843.2009.00520.x DO - 10.1111/j.1742-7843.2009.00520.x ID - Wallin2010 ER - TY - JOUR AU - Wallin, J. E. AU - Friberg, L. E. AU - Karlsson, M. O. PY - 2009 DA - 2009// TI - A tool for neutrophil guided dose adaptation in chemotherapy JO - Comput Methods Programs Biomed VL - 93 UR - https://doi.org/10.1016/j.cmpb.2008.10.011 DO - 10.1016/j.cmpb.2008.10.011 ID - Wallin2009 ER - TY - JOUR AU - Liu, Z. AU - Marcucci, G. AU - Byrd, J. C. AU - Grever, M. AU - Xiao, J. AU - Chan, K. K. PY - 2006 DA - 2006// TI - Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2'-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method JO - Rapid Commun Mass Spectrom VL - 20 UR - https://doi.org/10.1002/rcm.2423 DO - 10.1002/rcm.2423 ID - Liu2006 ER - TY - JOUR AU - Cashen, A. F. AU - Shah, A. K. AU - Todt, L. AU - Fisher, N. AU - DiPersio, J. PY - 2008 DA - 2008// TI - Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) JO - Cancer Chemother Pharmacol VL - 61 UR - https://doi.org/10.1007/s00280-007-0531-7 DO - 10.1007/s00280-007-0531-7 ID - Cashen2008 ER - TY - JOUR AU - Karahoca, M. AU - Momparler, R. L. PY - 2013 DA - 2013// TI - Pharmacokinetic and pharmacodynamic analysis of 5-aza-2'-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy JO - Clin Epigenetics VL - 5 UR - https://doi.org/10.1186/1868-7083-5-3 DO - 10.1186/1868-7083-5-3 ID - Karahoca2013 ER - TY - JOUR AU - Milhem, M. AU - Mahmud, N. AU - Lavelle, D. AU - Araki, H. AU - DeSimone, J. AU - Saunthararajah, Y. PY - 2004 DA - 2004// TI - Modification of hematopoietic stem cell fate by 5aza 2’deoxycytidine and trichostatin A JO - Blood VL - 103 UR - https://doi.org/10.1182/blood-2003-07-2431 DO - 10.1182/blood-2003-07-2431 ID - Milhem2004 ER - TY - JOUR AU - Young, J. C. AU - Wu, S. AU - Hansteen, G. AU - Du, C. AU - Sambucetti, L. AU - Remiszewski, S. PY - 2004 DA - 2004// TI - Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal JO - Cytotherapy VL - 6 UR - https://doi.org/10.1080/14653240410004899 DO - 10.1080/14653240410004899 ID - Young2004 ER - TY - JOUR AU - Chung, Y. S. AU - Kim, H. J. AU - Kim, T. M. AU - Hong, S. H. AU - Kwon, K. R. AU - An, S. PY - 2009 DA - 2009// TI - Undifferentiated hematopoietic cells are characterized by a genome-wide undermethylation dip around the transcription start site and a hierarchical epigenetic plasticity JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-01-197780 DO - 10.1182/blood-2009-01-197780 ID - Chung2009 ER - TY - JOUR AU - Suzuki, M. AU - Harashima, A. AU - Okochi, A. AU - Yamamoto, M. AU - Nakamura, S. AU - Motoda, R. PY - 2004 DA - 2004// TI - 5-Azacytidine supports the long-term repopulating activity of cord blood CD34(+) cells JO - Am J Hematol VL - 77 UR - https://doi.org/10.1002/ajh.20178 DO - 10.1002/ajh.20178 ID - Suzuki2004 ER - TY - JOUR AU - Negrotto, S. AU - Ng, K. P. AU - Jankowska, A. M. AU - Bodo, J. AU - Gopalan, B. AU - Guinta, K. PY - 2012 DA - 2012// TI - CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2011.207 DO - 10.1038/leu.2011.207 ID - Negrotto2012 ER - TY - JOUR AU - Greenberg, P. AU - Cox, C. AU - LeBeau, M. M. AU - Fenaux, P. AU - Morel, P. AU - Sanz, G. PY - 1997 DA - 1997// TI - International scoring system for evaluating prognosis in myelodysplastic syndromes JO - Blood VL - 89 ID - Greenberg1997 ER - TY - JOUR AU - Kantarjian, H. AU - Oki, Y. AU - Garcia-Manero, G. AU - Huang, X. AU - O'Brien, S. AU - Cortes, J. PY - 2007 DA - 2007// TI - Results of a randomized of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia JO - Blood VL - 109 UR - https://doi.org/10.1182/blood-2006-05-021162 DO - 10.1182/blood-2006-05-021162 ID - Kantarjian2007 ER -